Abstract Library

#3245 A single institution experience with peptide receptor radionuclide therapy (PRRT) in non-midgut neuroendocrine tumors (NETs)

Introduction: The NETTER-1 trial showed that patients with midgut neuroendocrine tumors (NETs) had longer progression-free survival (PFS) when treated with peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in combination with octreotide LAR vs octreotide LAR alone.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Duan H

Authors: Duan H, Ferri V, Fisher G, Shaheen S, Davidzon G,

Keywords: non-midgut NET, NET, PRRT, 177Lu-Dotatate,

#2165 A Pilot Study of the Cyclin Dependent Kinases 4, 6 Inhibitor Ribociclib in Patients with Foregut Neuroendocrine Tumors

Introduction: Increased cyclin dependent kinases 4, 6 (cdk 4/6) activity is noted in the majority of well differentiated foregut neuroendocrine tumors (fNETs) due to mutations in MENIN and other aberrations. These tumors also have preserved Rb function making cdk 4/6 inhibitors attractive agents for therapy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dasari A

Authors: Dasari A, Halperin D, Coya T, Mahvash A, Zorrilla I,

Keywords: Foregut NETs, ribociclib, cdk 4/6,

#214 Comparison of the AJCC and ENETS Staging Classifications for Neuroendocrine Tumors of the Pancreas

Introduction: The AJCC Cancer Staging Manual (7th edition, 2010) has introduced a novel TNM staging classification for pancreatic NETs. This classification has not yet been validated.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Strosberg J, Cheema A, Weber J, Kvols L,

Keywords: pancreatic neuroendocrine tumors, staging, AJCC, ENETS,